276 results about "High fat diet" patented technology

The invention discloses a strain of Witzia ciliaris with fat-reducing and weight-reducing functions, and belongs to the technical field of microorganisms. On the basis of reducing blood fat and weight, the screened Witzia ciliaris can inhibit the content and activity of fat synthase and relieve liver injury caused by high-fat diet, also has excellent acid resistance, bile salt resistance and efficient fat hydrolysis ability, is a strain of multifunctional Witzia ciliaris, and has good application prospects. The method has a wide application prospect in preparation of lipid-lowering, weight-losing and weight-losing products.

The invention discloses application of Osge as a molecular target to preparation of a medicine for preventing and / or treating fatty liver. According to the invention, the key effect of Osge as a therapeutic target in the treatment of fatty liver diseases caused by high fat diet is confirmed for the first time and is verified in a mouse model, and a method of overexpressing Osge through virus transfection proves that lipid deposition in liver tissues can be effectively reduced and liver balloon-like degeneration can be relieved by improving the expression level of Osge in the liver, so that the fatty liver diseases caused by high fat diet can be effectively treated. The accumulation of lipid droplets is reduced. The invention shows that Osge can be used as a new molecular target for preventing and treating fatty liver, and has important clinical application value in the aspect of treating metabolism-related fatty liver diseases.

The application discloses a Weizmannia coagulans with fat-reducing and weight-reducing functions, and belongs to the technical field of microorganisms. The Weizmannia coagulans screened by the application can inhibit the content and activity of fat synthesis enzyme on the basis of reducing blood fat and weight, can relieve liver damage caused by high-fat diet, has excellent acid tolerance, bile salt tolerance and high fat hydrolysis capacity, and is a multifunctional Weizmannia coagulans, and has a wide application prospect in the preparation of fat-reducing, weight-reducing and weight-losing products.

The invention discloses application of Prevotella copri as a children's metabolism-related fatty liver disease (MASLD) biomarker and a therapeutic target, relates to the fields of medical microbiology and metabonomics, and explores biological characteristics of the Prevotella copri and an action mechanism of the Prevotella copri in children's metabolism-related fatty liver disease (MASLD). The invention also analyzes the effect of Prevotella copri and its metabolite 5-aminovaleric acid in the development of children's metabolism-related fatty liver disease (MASLD), and provides a basis for developing a method for treating metabolism-related fatty liver disease (MASLD) based on intestinal microorganisms. According to the present invention, the Prevotella copri is subjected to intragastric administration to the mouse fed with the high fat diet, such that the liver fat change and the intestinal flora disorder aggravating are found; the metabolite 5-amino valeric acid of the Prevotella copri can be used for aggravating the adiposis of the liver cells. Therefore, the Prevotella copri and the metabolite 5-aminovaleric acid of the Prevotella copri can be used as a biomarker and a therapeutic target for diagnosis, treatment, prognosis evaluation or drug screening of the MASLD (Metabolism-related Fatty Liver Disease) of children.

The invention discloses an application of inulin in preparation of a medicine for treating polycystic ovarian syndrome, especially the polycystic ovarian syndrome caused by high fat diet. Starting from the pathogenesis of the PCOS, research is carried out in the direction of'regulating host-intestinal dialogue by dietary fibers, promoting a tryptophan-quinolinic acid metabolic pathway to enhance an NAD + de novo synthesis pathway and improving PCOS oxidative stress and insulin resistance ', pathophysiology of the PCOS is researched from a brand new perspective, and the pathogenesis of a patient suffering from the PCOS is comprehensively researched in combination with metabonomics. And a new thought and a new target spot are provided for subsequent treatment.

The invention discloses an establishment method and application of a damp-heat intestine accumulation type ulcerative colitis animal model, and belongs to the field of animal models.The establishment method comprises the steps that S1, high-fat feed treatment is conducted, specifically, experimental animals freely eat high-fat feed for 6-10 weeks from the first day; s2, DSS treatment: feeding 1.5% (w / v) DSS solution to the experimental animal for 2 weeks; and S3, observing the damp-heat syndrome type and ulcerative colitis related indications of the experimental animals, and selecting the experimental animals meeting the scoring standard, thereby establishing the ulcerative colitis mouse model. Aiming at the situation that most patients induce ulcerative colitis due to excess energy due to the change of dietary structures and lifestyles at present, the invention constructs and evaluates the damp-heat accumulation type ulcerative colitis mouse model by inducing internal dampness by a direct pathogenesis (high fat diet), which is closer to the actual situation of clinical patients. Therefore, a model and reference are provided for research and treatment of pathology of the damp-heat accumulation type ulcerative colitis and pharmacological mechanisms of traditional Chinese medicines.

The present application relates to use of Ligilactobacillus salivarius in preparing a drug for preventing and / or treating diseases associated with overweight and / or obesity . The strain can inhibit the weight growth of a high-fat diet-induced obesity model mouse, reduce the blood lipid level of the high-fat diet-induced obesity model mouse, improve the liver injury index of the high-fat diet-induced obesity model mouse, reduce the area of white adipose cells of the high-fat diet-induced obesity model mouse, improve the colon GLP-1 level of the high-fat diet-induced obesity model mouse, improve the intestinal flora imbalance of the high-fat diet-induced obesity model mouse, and improve the liver glycolipid metabolism of the high-fat diet-induced obesity model mouse; and reduce the waist circumference, hip circumference, body fat mass, BMI, and weight of overweight and overweight and / or obesity volunteers, and maintain the muscle content, promoting overweight and overweight and / or obesity people to carry out safe, effective, and sustainable weight management.

The application discloses a method for constructing a mouse model of atherosclerosis induced without high-fat diet, and relates to the technical field of disease model construction.The mouse model construction method provided by the application obtains a mouse model that spontaneously exhibits atherosclerosis symptoms without high-fat diet induction.The mouse model of atherosclerosis induced without high-fat diet can be used for researching the pathogenesis of atherosclerosis and screening and evaluating drugs for atherosclerosis.

The invention discloses application of vanillyl alcohol in preparation of medicines for preventing and treating fatty liver, obesity or diabetes, and belongs to the technical field of medicines. The invention is implemented in vitro and in vivo, and aims to solve the problem of lack of low-toxicity natural small molecule drugs for effectively preventing and treating fatty liver, obesity or diabetes at present. The embodiment of the invention proves that the vanillyl alcohol can obviously reduce high-fat diet induced mouse fat deposition, reduce in-vivo and in-vitro liver TG content and lipid droplet accumulation, enhance glucose tolerance of the high-fat diet induced mouse and improve insulin resistance of the high-fat diet induced mouse. As a natural antioxidant, vanillyl alcohol has an obvious relieving effect on energy metabolism disorder and oxidative stress induced by high fat. As a low-toxicity natural small molecule, vanillyl alcohol can improve glucose and lipid metabolism disorder induced by high fat, is low in price, and has application value in preparation of medicines for preventing and treating fatty liver, obesity or diabetes mellitus.

The invention provides an application of Fuxia dothidei YG0564 in preparation of a composition for preventing, relieving and / or treating individual sexual precocity, growth and development impairment and / or obesity. It is found that the Fuxia dolferi YG0564 can effectively prevent, relieve and / or treat sexual precocious puberty, growth and development damage and / or obesity of individuals, and especially has a remarkable improvement effect on the diseases caused by high-fat diet. For sexual precocious puberty or damaged growth and development induced by high-fat diet, the Fuxia dolferi YG0564 is applied to individuals in the early stage or early stage of puberty, the protection effect of the Fuxia dolferi YG0564 can be continued to the adult stage, and the fundamental problem of growth and development is solved through staged medication. Therefore, a potential probiotic treatment scheme is provided for precocious puberty, growth and development damage and / or obesity of individuals, and the probiotic composition is convenient to apply, high in patient acceptability and low in treatment cost, so that the probiotic composition has good clinical transformation value and social benefits.

The present invention relates to the application of saliva combined with lactobacillus in the preparation of a drug for treating obesity, and belongs to the field of biomedicine technology. The present invention provides the application of saliva combined with lactobacillus XA-1416 in the preparation of a drug for preventing and / or treating obesity, or preventing and / or treating obesity-related diseases. This strain can inhibit the weight gain of mice with obesity model induced by high-fat diet, reduce the blood lipid level of mice with obesity model induced by high-fat diet, improve the liver damage index of mice with obesity model induced by high-fat diet, reduce the area of ​​white fat cells in mice with obesity model induced by high-fat diet, promote the conversion of intestinal conjugated bile acid to free bile acid in mice with obesity model induced by high-fat diet, increase the level of intestinal FXR antagonist in mice with obesity model induced by high-fat diet, improve the intestinal flora imbalance of mice with obesity model induced by high-fat diet, inhibit fat accumulation in Hep G2 model, and inhibit differentiation into adipocytes in 3T3-L1 model.

The invention discloses application of a lucid ganoderma extract combined with clostridium butyricum in preparation of fat-reducing food or medicine. The invention finds that the ganoderma lucidum extract is combined with clostridium butyricum for use, so that the weight gain of a mouse induced by high-fat diet can be obviously slowed down, the epididymal fat weight of the high-fat mouse is reduced, and the lipid accumulation in the liver and serum of the mouse is reduced; according to the present invention, with the application of the polypeptide, the fat cell size is reduced, the expression of the key gene mRNA related to lipid metabolism and synthesis in the mouse liver is reduced, the intestinal flora of the mouse is regulated, the obesity can be well improved, and the important application prospect in the preparation of the drugs or food for treating diabetes, reducing blood fat, obesity and non-alcoholic fatty liver disease is provided.

The invention belongs to the field of biotechnology and nutritional medicine, relates to a maternal obesity intervention preparation, and particularly relates to a preparation method of a plant embryo fermentation product and application of the plant embryo fermentation product in blocking of trans-generation delivery metabolic diseases. FWG is prepared through a probiotic fermentation technology, obesity, glucose and lipid metabolism disorder and oxidative stress induced by high-fat diet of a parent body can be remarkably improved, and cross-generation transmission of metabolic diseases is blocked by adjusting composition of intestinal flora of the parent body and offspring and a hypothalamic PI3K-Akt signal channel. The invention reveals that maternal FWG intervention passes through a mechanism that a PI3K-Akt pathway is dominated and multiple pathways are coordinated on the transcriptome level for the first time, the HFD-induced offspring hypothalamus metabolism programming abnormality is reversed, and a new central regulation target is provided for cross-generation metabolic disease prevention. The FWG is a wheat processing byproduct, is free of chemical additives, is suitable for long-term dietary supplement, is a natural and safe nutrition intervention scheme, and is suitable for the field of maternal and infant health.

The invention relates to application of 9-cis-retinoic acid in preparation of products for treating, preventing or improving obesity, and belongs to the technical field of biological medicine. Experimental evaluation of obese mice induced by high-fat diet proves that the 9-cis-retinoic acid can reduce blood fat and improve the glycometabolism function, and lipid accumulation of the liver is improved mainly by increasing expression of main regulatory protein PPAR-alpha oxidized by liver beta, so that the 9-cis-retinoic acid can be used for preparing medicines for treating obesity. The traditional Chinese medicine composition can be used for treating, preventing or improving metabolic symptoms caused by high fat diet, and a new strategy is provided for treating obesity and related metabolic syndromes. Besides, 9-cis-retinoic acid is a natural active metabolite of vitamin A, does not show obvious toxic reaction in animal experiments, and has better biocompatibility.

The invention belongs to the technical field of natural products, and provides application of fucoxanthin in preparation of oral anti-alopecia drugs. Animal experiments find that long-term high-fat diet can lead to large-piece shedding of hair accompanied by skin inflammation, and fucoxanthin has a treatment effect on high-fat diet induced mouse back hair shedding and skin inflammation, can obviously relieve high-fat diet induced subcutaneous cholesterol crystal accumulation and sebaceous gland cell hypertrophy, and has the effects of preventing and treating the high-fat diet induced mouse back hair shedding and skin inflammation and preventing and treating the high-fat diet induced mouse back hair shedding and the high-fat diet induced sebaceous gland cell hypertrophy. And skin epidermal hyperplasia and cuticle thickening induced by high fat diet can be improved. Besides, cell experiments also find that fucoxanthin intervention can reduce oleic acid infiltration of the hair follicle stem cells and reduce oleic acid induced death and apoptosis of the hair follicle stem cells, and prove that fucoxanthin has a protection effect on the hair follicle stem cells, has low toxic and side effects on cells and animals as a natural algae extract, and has a good application prospect. Good clinical application prospects are realized.

The invention relates to a probiotic preparation containing a BL11 strain and capable of improving obesity-related metabolism and senescence indexes of middle-aged and elderly people and application of the probiotic preparation. The strain in the probiotic preparation is composed of a bifidobacterium longum subsp. Longum BL11 strain and a pediococcus acidilactici PA53 strain. The two strains can cooperate with each other and promote each other, and have a synergistic effect in the aspect of improving obesity-related metabolic indexes, which is specifically embodied in that: the weight increase and body fat rate of mice fed with high fat diet can be reduced; the low-density lipoprotein level, the total cholesterol level and the triglyceride level are reduced, and the high-density lipoprotein level is improved; fasting blood-glucose, glycosylated hemoglobin level and insulin resistance index are reduced; chronic inflammation is relieved; meanwhile, the composition also has excellent performance in the aspect of improving senescence-related indexes, the content of malondialdehyde in serum can be reduced, the activity of superoxide dismutase and glutathione peroxidase can be improved, and the activity of telomerase can be improved.

The invention discloses application of breast milk-derived lactobacillus gasseri in reducing weight, reducing blood fat, preventing and treating type 2 diabetes mellitus, relieving intestinal leakage and inhibiting intestinal pathogens, and belongs to the technical field of microorganisms and the technical field of medicines. The invention provides a new application of lactobacillus gasseri in reducing weight, reducing blood fat, preventing and treating type 2 diabetes, relieving intestinal leakage and inhibiting intestinal pathogens. The traditional Chinese medicine composition can effectively prevent weight gain, body fat rate increase, low-density lipoprotein cholesterol and triglyceride increase of mice caused by high-fat diet, inhibit postprandial blood sugar and insulin resistance index increase, inhibit intestinal mucosa damage and growth of intestinal pathogenic bacteria, and effectively improve chronic diseases of mice with high-fat diet. Therefore, the lactobacillus gasseri FN136 has a huge application prospect in preparation of products for reducing weight, reducing blood fat, preventing and treating type 2 diabetes mellitus, relieving intestinal leakage and inhibiting intestinal pathogens.

The invention provides an application of lactobacillus rhamnosus NKU FL1-8 in resisting obesity, serum inflammation and cognitive impairment caused by high fat diet, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus NKU FL1-8 has the advantages that the lactobacillus rhamnosus NKU FL1-8 can be used for resisting the obesity, the serum inflammation and the cognitive impairment caused by high fat diet; the invention finds that the lactobacillus rhamnosus NKU FL1-8 can obviously reduce adipose tissue increase caused by high-fat diet, relieve liver function impairment caused by high-fat diet, inhibit serum inflammation caused by high-fat diet, improve cognitive impairment caused by high-fat diet, strengthen intestinal barrier, increase the content of short-chain fatty acid in cecum and excrement and improve the immunity of the cecum. The intestinal flora is regulated, and the diversity of the intestinal flora is improved, so that related diseases caused by high-fat diet are effectively resisted.

The invention provides an application of liquiritin in preparation of a PPAR gamma receptor partial agonist. Through a structure-based high-throughput virtual screening technology, it is found that liquiritin can be used as a partial agonist of a PPAR gamma receptor, and the relative activation efficiency of liquiritin is 35.9% of that of rosiglitazone; in-vitro experiments prove that liquiritin can remarkably promote glucose uptake and consumption of HepG2 cells and does not induce adipocyte differentiation; in-vivo experiments prove that liquiritin can effectively improve the blood glucose level of an insulin resistance mouse model induced by high fat diet and reduce the level of serum proinflammatory factors. Compared with thiazolidinedione compounds, liquiritin not only can relieve and treat insulin resistance or related metabolic diseases, but also does not cause adverse reactions such as weight gain, fat accumulation and myocardial hypertrophy, provides a new candidate compound for developing safe and effective anti-diabetic drugs, and has a wide application prospect.

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non- alcoholic fatty liver disease (NAFLD) is the most common liver disease with a worldwide prevalence estimated at 30% of the general population. To better understand the influence of MASLD progression on cardiovascular disease, the aim of the study was to develop a new physiopathological mouse model able to develop progressive MASLD, along with atherosclerosis development, in a reasonable period of time. LDLr - / - mice were crossed with PPARα-deficient mice in order to obtain LDLr- / - mice expressing (LDLr - / - PPARα + / +) or not (LDLr - / - PPARα - / -) PPARα. Female mice were challenged with a high-fat diet during 12 and 18 weeks. Histological liver analysis showed that, compared to control diet, LDLr - / - PPARα + / + mice under high fat diet developed mostly steatosis at 12 weeks, and then exhibited all characteristics of human MASLD, namely the steatosis, inflammation and ballooning-triad, with presence of fibrosis at 18 weeks. This MASLD progression over time in LDLr - / - PPARα + / + was aggravated in LDLr - / - PPARα + / + mice. The present invenion defines a new relevant mouse model of progressive MASLD, developing all the characteristics of human MASLD (steatosis, inflammation, ballooning, fibrosis), in a relatively short time period (12-18 weeks), along with simultaneous atherosclerosis development.

The invention discloses a highly efficient cholesterol-lowering Lactobacillus paracasei I MAUJBC1 and its application, and relates to the technical field of functional microorganisms. The strain disclosed in the invention can alleviate weight gain caused by a high-fat diet, improve elevated blood lipid levels; reduce the expression level of cholesterol synthesis genes in the liver; significantly increase the expression level of cholesterol metabolism genes in the liver, and play a cholesterol-lowering role; and increase the abundance of beneficial bacteria in the intestinal flora, effectively improve the intestinal flora disorder caused by a high-fat diet, and play a role in alleviating hyperlipidemia.

The invention discloses edible nano cellulose aerogel capable of absorbing oil and inhibiting fat as well as a preparation method and application thereof, and belongs to the technical field of biology, bamboo shoot cellulose nanofiber (CNF), carrageenan (Car) and curcumin (Cur) are used as raw materials, and the oil-absorbing composite porous aerogel with the porosity of 91.1-98.7% is prepared through a vacuum freeze-drying method. The oleophylic and lipid-lowering effects of the Car-CNF-Cur aerogel are researched by simulating gastrointestinal digestion and high fat diet (HFD) mice, the result shows that the ratio of CNF to carrageenan is 0.8: 1-1: 0.8, the edible Car-CNF-Cur aerogel modified by 1-2.5 g / L of curcumin and 1-3% of PDMS has a uniform porous structure, the oil absorption performance is 24.45 g / g, and the hydrophobic angle is 144 degrees; the composition can inhibit inflammation and lipopolysaccharide generation, is non-toxic, and can regulate the composition of intestinal microbiota, thereby safely reducing digestion and absorption of intake fat; the Car-CNF-Cur aerogel provides a basis for the development of an edible oleophylic composite material.

The application discloses a polypeptide composition for treating obesity and related metabolic diseases and application thereof. The polypeptide composition comprises polypeptide 1 and polypeptide 2, wherein the amino acid sequence of the polypeptide 1 is shown as SEQ ID NO. 1, can be specifically combined with the CD105 receptor on the surface of MSCs and the AdipoR1 receptor of adipocytes; the amino acid sequence of the polypeptide 2 is shown as SEQ ID NO. 2, can target adipose tissue and regulate glycolipid metabolism. The polypeptide composition is combined with fat-derived mesenchymal stem cells (MSCs) and applied to a high-fat-diet obese mouse model, and the results show that the composition has a significant synergistic effect in reducing body fat, improving the morphology of adipose tissue, regulating serum metabolic factors and inflammatory factors, and has no obvious organ toxicity. The application provides a new effective strategy and a safe and reliable pharmaceutical composition for treating obesity and related metabolic diseases.

The invention discloses application of a histone acetyltransferase inhibitor in preparation of a medicine for improving liver fatty degeneration. The invention discloses application of a histone acetyltransferase inhibitor for selectively inhibiting Gcn5 acetylation of histone H3 in preparation of drugs for treating and / or preventing diseases caused by liver fatty degeneration. And the histone acetyltransferase inhibitor for selectively inhibiting acetylation of Gcn5 on histone H3 is CPTH2. The compound CPTH2 reduces the protein abundance of a liver lipid synthesis transcription factor SREBP1c by inhibiting the acetylation activity of H3K9 and H3K14, and obviously improves the liver fatty degeneration of C57BL / 6J mice fed with high fat diet.

The present invention discloses a method of treatment and / or prevention of obesity using a composition comprising of brominated diterpenes from red algae of the genus Laurencia as active ingredients and preferably the diterpene neorogioldiol, isolated from Laurencia sp. or chemically synthesized. The said diterpenes suppress pre-adipocyte differentiation to adipocytes, modulate metabolism in 3T3-L1 cells, restrict weight gain and development of glucose intolerance when administered intraperitoneally in vivo, in the mouse model of high fat diet-induced obesity.

Compositions and formulations of synthetic MXRA8-Fc fusion proteins are provided, as well as methods of use thereof. Methods include neutralizing TSP1 / MXRA8 interactions in a subject by administering a synthetic MXRA8-Fc fusion protein, such that the synthetic MXRA8-Fc fusion protein binds to TSP1 to inhibit the TSP1 from binding with MXRA8. Methods also include treating obesity such as high fat diet (HFD)-induced obesity, and treating obesity-associated metabolic diseases such as type 2 diabetes by administering a synthetic MXRA8-Fc fusion protein.

The invention discloses an application of an intestinal strain in preparation of a cholesterol-lowering product, and belongs to the technical field of microbial medicines. The intestinal bacterial strain is Oscillibacter ruminant, the viable bacteria concentration of the intestinal bacterial strain is controlled to be (4.8-5.2) * 10 < 9 > CFU / mL, the intestinal bacterial strain can be prepared into bacterial liquid, freeze-dried powder, capsules or tablets and other dosage forms, and pharmaceutically acceptable auxiliary materials such as lactose and microcrystalline cellulose can be added. According to the cholesterol-lowering product, the total cholesterol, triglyceride and low-density lipoprotein cholesterol level of an object can be remarkably reduced under the action of peste des petits ruminants, and meanwhile, the high-density lipoprotein cholesterol level is increased; in addition, abnormal blood glucose induced by high-fat diet can be improved, arterial lipid accumulation is reduced, and the plaque area proportion of atherosclerotic lesions is improved.

The invention relates to the technical field of biological medicines, and discloses application of INHBC as a target spot in prevention and / or treatment of metabolic diseases. Specifically, the invention relates to application of substances for promoting INHBC gene expression or improving protein activity in preparation of products for preventing and / or treating metabolic diseases, and the metabolic diseases comprise diseases caused by energy metabolism disorder, such as obesity, diabetes, fatty liver disease, hyperlipidemia and the like. According to the application disclosed by the invention, liver specific overexpression or INHBC knock-in can improve mouse liver fatty degeneration and abnormal glucose metabolism induced by high fat diet, and in addition, the heat production activity of mouse adipose tissues can be enhanced, so that obesity induced by high fat diet is inhibited; the compound has an important application value in preventing and / or treating metabolic diseases such as obesity, type 2 diabetes and fatty liver diseases.

Disclosed herein are a means to prevent and / or ameliorate age, disease and obesity associated metabolic diseases, such as diabetes and impaired glucose tolerance. Also disclosed are compositions and methods that relate to the findings that GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis in aged mice administered a high fat diet. In particular, the methods and compositions described herein relate to increasing the level of GDF11 in a subject, thereby treating or preventing the development of obesity in the subject, reducing the metabolic consequences of obesity and improving the subject's metabolic health.

Provided is a Bifidobacterium bifidum strain, Bifidobacterium bifidum ibiome001, which can significantly reduce body weight gain and white adipose tissue weight gain of high fat diet-induced obese and diabetic mice, and enhances expression of lipolytic genes ATGL and HSL. Moreover, Bifidobacterium bifidum ibiome001 can significantly lower fasting blood glucose levels, area under curves (AUCs) of the oral glucose tolerance (OGTT) curve, plasma glycated hemoglobin levels and insulin levels of diabetic mice. It is suggested that Bifidobacterium bifidum ibiome001 is a promising potential probiotic strain for the treatment of metabolic syndrome such as obesity, diabetes and the like, which is more effective than other Bifidobacterium strains / compositions.